search
Back to results

Systemic Hormones and Muscle Protein Synthesis

Primary Purpose

Sarcopenia, Muscle Hypotrophy, Muscle Atrophy

Status
Unknown status
Phase
Phase 3
Locations
United Kingdom
Study Type
Interventional
Intervention
Sustanon 250
Zoladex
Placebo
Sponsored by
University of Nottingham
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Sarcopenia focused on measuring Protein Synthesis, Hypertrophy, Testosterone

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

Young (18-30y) and old (60-75y) males who are generally healthy

Exclusion Criteria:

  • Participation in a formal exercise regime
  • BMI < 18 or > 30 kg·m2
  • Active cardiovascular disease:

    • uncontrolled hypertension (BP > 160/100),
    • angina,
    • heart failure (class III/IV),
    • arrhythmia,
    • right to left cardiac shunt,
    • recent cardiac event
  • Taking beta-adrenergic blocking agents, statins, non-steroidal anti-inflammatory drugs or HRT
  • Cerebrovascular disease:

    • previous stroke,
    • aneurysm (large vessel or intracranial)
    • epilepsy
  • Respiratory disease including:

    • pulmonary hypertension,
    • COPD,
    • asthma,
  • Metabolic disease:

    • hyper and hypo parathyroidism,
    • Hypo and hyper gonadism
    • untreated hyper and hypothyroidism,
    • Cushing's disease,
    • type 1 or 2 diabetes
  • Active inflammatory bowel or renal disease
  • Malignancy
  • Altered hormonal profile
  • Recent steroid treatment (within 6 months) or hormone replacement therapy
  • Clotting dysfunction
  • Musculoskeletal or neurological disorders
  • Family history of early (<55y) death from cardiovascular disease

Sites / Locations

  • Royal Derby Hospital Medical School

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Arm Label

Old Testosterone trained

Old Placebo trained

Young Zoladex trained

Young placebo trained

Arm Description

8 old participants (65-75 years old) who will receive resistance exercise training and Testosterone (Sustanon 250: 250 mg every 2wks) Drug name: Sustanon 250 Generic Name: Testosterone Proprietary Name: N/A Formulation: 250mg of Testosterone in 1ml volume Dose: 250mg of testosterone Frequency: every 2 weeks Route: intramuscular injection

8 old participants (65-75 years old) who will receive resistance exercise training and Placebo every two weeks.

8 young participants (18-30 years old) who will receive resistance exercise training and Testosterone inhibitor (3.6mg Zoladex subcutaneous injection, one time over the study) Drug name: Zoladex Generic Name: Gonadotropin-releasing hormone analogue; Goserelin Proprietary Name: N/A Formulation: Solution for injection Dose: 3.6mg Frequency: Single injection one time over the study. Route: Subcutaneous injection (abdomen) performed by clinician.

8 young participants (18-30 years old) who will receive resistance exercise training and placebo, one time over the study.

Outcomes

Primary Outcome Measures

Muscle Protein Synthesis
Comparison of muscle protein synthesis between young and older individuals when their testosterone levels decrease and increase, respectively; in response to 6 weeks whole body resistance exercise training

Secondary Outcome Measures

Full Information

First Posted
February 10, 2017
Last Updated
February 22, 2019
Sponsor
University of Nottingham
search

1. Study Identification

Unique Protocol Identification Number
NCT03054168
Brief Title
Systemic Hormones and Muscle Protein Synthesis
Official Title
The Regulation of Skeletal Muscle Protein Synthesis by Systemic Hormones and Its Influence on Ageing and Anabolic Resistance
Study Type
Interventional

2. Study Status

Record Verification Date
February 2019
Overall Recruitment Status
Unknown status
Study Start Date
December 15, 2016 (Actual)
Primary Completion Date
November 15, 2018 (Actual)
Study Completion Date
February 15, 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Nottingham

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study evaluates the effect of increase in testosterone levels in older males and the effects of decrease in testosterone levels in young males on muscle protein synthesis.
Detailed Description
Skeletal muscle represents the largest organ in the body, comprising >50% of total body mass. The function of skeletal muscle is best understood for its role in locomotion and providing mechanical support to the skeleton to facilitate movement. However, skeletal muscles are also important for maintaining whole-body metabolic health. For example, muscles also act as a site for glucose disposal thereby acting to maintain whole-body glycaemic control. In addition, skeletal muscles represent a vast protein store, the amino acids from which can be used in times of fasting, infection and disease to provide energy to maintain other critical organs. Exercise (resistance type exercise (RE-T) in particular) still remains the most effective means by which to maintain and increase muscle mass through stimulation of muscle protein synthesis (MPS), despite this, how exercise regulates these changes in muscle mass is still unknown. A number of pathways have been inferred as key, however it is clear from a number of studies that systemic hormone levels, testosterone in particular, may provide a significant contribution. It is well known that chronic androgenic hormone deficiency can lead to a loss of lean body mass and strength, which can in turn contribute to impaired physical function. Furthermore, when testosterone levels are pharmacologically reduced (using a gonadotropin releasing hormone analogue) in healthy young males, resistance exercise training induced increases in muscle mass and strength are absent. Whilst systemic hormone levels are carefully maintained in youth (unless illness or deficiency is present), levels of these hormones decrease with age, particularly in those that are not regularly physically active, indeed approximately 25-30% of older men have levels of testosterone which are below the threshold used to define hypogonadism. Therefore, there is significant need to understand the underlying mechanisms behind hormonally induced muscle mass regulation. Furthermore, in older age there is a resistance to traditional anabolic stimuli such as nutrition or resistance exercise, with older adults showing a blunted-anabolic hormonal profile in response to resistance training compared to young. These impairments to hormonal regulation with ageing may in part be responsible for the slow decline in muscle mass with age known as sarcopenia. Whilst all muscle-wasting conditions are of considerable concern, it is the loss of muscle in older age that poses the greatest socio-economic burden. Therefore there is a significant clinical need to identify contributing factors to this muscle loss so that they can be specifically targeted for intervention (i.e., pharmacological hormonal therapies). The aims of this project are two fold: 1) Firstly we aim to investigate the impact of systemic hormone levels on control of muscle mass in healthy young adults undertaking a resistance exercise training program, we hypothesize that reduction of hormone levels in systemically normal young adults will impair MPS and muscle mass gains in response to resistance exercise training. 2) Secondly we aim to investigate the impact of enhancing testosterone levels in older adults on responsiveness to resistance exercise training and the contribution of systemic testosterone levels to muscle mass regulation in ageing, we hypothesize that increasing testosterone levels in older males will improve responsiveness to anabolic stimuli (RE-T).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sarcopenia, Muscle Hypotrophy, Muscle Atrophy
Keywords
Protein Synthesis, Hypertrophy, Testosterone

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
To achieve our aims we will recruit 16 young healthy males (Age: 18-30 y; BMI: 18-30kg/m2) and 16 older healthy males (Age: 65-75 y; BMI: 18-30kg/m2). Volunteers will then be randomly assigned to a testing group; 1) Young placebo trained (N=10), 2) Young gonadotropin releasing hormone analogue trained (3.6mg Zoladex subcutaneous injection (every 4 weeks) N=10), 3) Old placebo trained (N=10) and 4) Old Testosterone trained (Sustanon 250: 250 mg every 2-3wks intramuscular injection, N=10). All participants will receive whole body resistance exercise training for six weeks.
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
34 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Old Testosterone trained
Arm Type
Experimental
Arm Description
8 old participants (65-75 years old) who will receive resistance exercise training and Testosterone (Sustanon 250: 250 mg every 2wks) Drug name: Sustanon 250 Generic Name: Testosterone Proprietary Name: N/A Formulation: 250mg of Testosterone in 1ml volume Dose: 250mg of testosterone Frequency: every 2 weeks Route: intramuscular injection
Arm Title
Old Placebo trained
Arm Type
Placebo Comparator
Arm Description
8 old participants (65-75 years old) who will receive resistance exercise training and Placebo every two weeks.
Arm Title
Young Zoladex trained
Arm Type
Experimental
Arm Description
8 young participants (18-30 years old) who will receive resistance exercise training and Testosterone inhibitor (3.6mg Zoladex subcutaneous injection, one time over the study) Drug name: Zoladex Generic Name: Gonadotropin-releasing hormone analogue; Goserelin Proprietary Name: N/A Formulation: Solution for injection Dose: 3.6mg Frequency: Single injection one time over the study. Route: Subcutaneous injection (abdomen) performed by clinician.
Arm Title
Young placebo trained
Arm Type
Placebo Comparator
Arm Description
8 young participants (18-30 years old) who will receive resistance exercise training and placebo, one time over the study.
Intervention Type
Drug
Intervention Name(s)
Sustanon 250
Other Intervention Name(s)
Testosterone
Intervention Description
The frequency of the injection will be every 2 weeks, 250mg of testosterone, intramuscular injection.
Intervention Type
Drug
Intervention Name(s)
Zoladex
Other Intervention Name(s)
Gonadotropin-releasing hormone analogue; Goserelin
Intervention Description
The frequency of the injection will be just one injection, 3.6 mg of Zoladex, Subcutaneous injection (abdomen).
Intervention Type
Other
Intervention Name(s)
Placebo
Other Intervention Name(s)
Saline
Primary Outcome Measure Information:
Title
Muscle Protein Synthesis
Description
Comparison of muscle protein synthesis between young and older individuals when their testosterone levels decrease and increase, respectively; in response to 6 weeks whole body resistance exercise training
Time Frame
0-6 Weeks

10. Eligibility

Sex
Male
Gender Based
Yes
Gender Eligibility Description
All participants are male.
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Young (18-30y) and old (60-75y) males who are generally healthy Exclusion Criteria: Participation in a formal exercise regime BMI < 18 or > 30 kg·m2 Active cardiovascular disease: uncontrolled hypertension (BP > 160/100), angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt, recent cardiac event Taking beta-adrenergic blocking agents, statins, non-steroidal anti-inflammatory drugs or HRT Cerebrovascular disease: previous stroke, aneurysm (large vessel or intracranial) epilepsy Respiratory disease including: pulmonary hypertension, COPD, asthma, Metabolic disease: hyper and hypo parathyroidism, Hypo and hyper gonadism untreated hyper and hypothyroidism, Cushing's disease, type 1 or 2 diabetes Active inflammatory bowel or renal disease Malignancy Altered hormonal profile Recent steroid treatment (within 6 months) or hormone replacement therapy Clotting dysfunction Musculoskeletal or neurological disorders Family history of early (<55y) death from cardiovascular disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Philip J Atherton, Professor
Organizational Affiliation
The University of Nottingham
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Nathaniel Szewczyk, Ass. Proff
Organizational Affiliation
The University of Nottingham
Official's Role
Study Chair
Facility Information:
Facility Name
Royal Derby Hospital Medical School
City
Derby
State/Province
Derbyshire
ZIP/Postal Code
DE22 3DT
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
9626114
Citation
Mauras N, Hayes V, Welch S, Rini A, Helgeson K, Dokler M, Veldhuis JD, Urban RJ. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab. 1998 Jun;83(6):1886-92. doi: 10.1210/jcem.83.6.4892.
Results Reference
background
PubMed Identifier
16868226
Citation
Kvorning T, Andersen M, Brixen K, Madsen K. Suppression of endogenous testosterone production attenuates the response to strength training: a randomized, placebo-controlled, and blinded intervention study. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1325-32. doi: 10.1152/ajpendo.00143.2006. Epub 2006 Jul 25.
Results Reference
background
PubMed Identifier
8409184
Citation
Abbasi AA, Drinka PJ, Mattson DE, Rudman D. Low circulating levels of insulin-like growth factors and testosterone in chronically institutionalized elderly men. J Am Geriatr Soc. 1993 Sep;41(9):975-82. doi: 10.1111/j.1532-5415.1993.tb06764.x.
Results Reference
background
PubMed Identifier
11158037
Citation
Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR; Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001 Feb;86(2):724-31. doi: 10.1210/jcem.86.2.7219.
Results Reference
background
PubMed Identifier
17194250
Citation
Baker JR, Bemben MG, Anderson MA, Bemben DA. Effects of age on testosterone responses to resistance exercise and musculoskeletal variables in men. J Strength Cond Res. 2006 Nov;20(4):874-81. doi: 10.1519/R-18885.1.
Results Reference
background
PubMed Identifier
19001042
Citation
Kumar V, Selby A, Rankin D, Patel R, Atherton P, Hildebrandt W, Williams J, Smith K, Seynnes O, Hiscock N, Rennie MJ. Age-related differences in the dose-response relationship of muscle protein synthesis to resistance exercise in young and old men. J Physiol. 2009 Jan 15;587(1):211-7. doi: 10.1113/jphysiol.2008.164483. Epub 2008 Nov 10.
Results Reference
background
PubMed Identifier
21058750
Citation
Vingren JL, Kraemer WJ, Ratamess NA, Anderson JM, Volek JS, Maresh CM. Testosterone physiology in resistance exercise and training: the up-stream regulatory elements. Sports Med. 2010 Dec 1;40(12):1037-53. doi: 10.2165/11536910-000000000-00000.
Results Reference
background

Learn more about this trial

Systemic Hormones and Muscle Protein Synthesis

We'll reach out to this number within 24 hrs